Enovix Corporation — FY2022 Form 10-K
Business context and reporting period. The filing covers the fiscal year ended January 1, 2023; the prior comparable fiscal year ended January 2, 2022. Enovix develops and manufactures silicon-anode lithium-ion batteries using a proprietary 3D cell architecture. Commercial production and initial product shipments began in Q2 2022 at its Fremont Fab-1 facility; the company remains in early commercialization and manufacturing scale-up.
Financial and operating performance
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $6.2 million | $0 |
| Cost of revenue / gross loss | $23.2 million / $17.0 million loss | $2.0 million / $2.0 million loss |
| Research and development | $58.1 million | $37.9 million |
| Selling, general and administrative | $52.0 million | $29.7 million |
| Operating loss | $132.0 million | $69.5 million |
| Net loss | $51.6 million | $125.9 million |
| Net cash used in operating activities | $82.7 million | $51.3 million |
| Capital expenditures | $36.2 million | $43.6 million |
| Free cash flow, company-defined | $(119.0) million | $(94.9) million |
FY2022 revenue consisted almost entirely of $6.2 million in engineering/service revenue; product revenue was immaterial. One customer contributed $5.0 million. The fourth quarter included $1.1 million of service revenue tied to custom-cell deliveries. The filing does not provide a clear total-revenue figure for Q4.
Net loss improved year over year largely because of a $75.2 million non-cash gain from the decrease in fair value of private placement warrants; the comparable FY2021 period had a $56.1 million warrant-related loss. Adjusted EBITDA, a non-GAAP measure, was a loss of $83.5 million versus a loss of $57.3 million. FY2022 basic loss per share was $0.34 and diluted loss per share was $0.82, with warrant accounting affecting diluted EPS.
At year-end, cash and cash equivalents were $322.9 million, working capital was $306.6 million, and accumulated deficit was $384.8 million. The company had no outstanding debt. Total liabilities included a $49.1 million warrant liability and $8.9 million in operating lease liabilities. Management expected cash to fund requirements for at least the next 12 months, while noting that additional financing may be needed for future operations and expansion.
Material changes versus the prior period
- Revenue began in Q2 2022, but remained small and predominantly service-based; the company had no revenue in FY2021.
- Operating loss widened to $132.0 million from $69.5 million, reflecting higher R&D and SG&A, production ramp costs, and a $4.9 million equipment impairment.
- Net loss narrowed, mainly due to the warrant fair-value gain, while operating cash use increased by $31.4 million.
- Fab-1 production advanced: Q4 shipments reached 4,442 cells, and volume-weighted yield for the final four weeks of Q4 was 42.9%, versus 16.4% at the end of Q3.
- Cash declined from $385.3 million to $322.9 million. FY2022 financing cash inflows were primarily $52.8 million of net proceeds from public warrant exercises.
Outlook, commentary, risks and contingencies
- Manufacturing plans: The company planned smartphone-sized cell production at Fab-1 in 2023 and installation of its Gen2-compatible Agility Line by year-end 2023. It targeted Gen2 production at Fab-2 in 2024; the filing states that a suitable Fab-2 facility had not yet been located. At 80% overall equipment effectiveness, Gen2 lines were estimated to produce 9.5 million to 18.9 million batteries annually, depending on cell size. These are plans and estimates, not assured results.
- Scale-up and customer conversion: Management said manufacturing yield, throughput, equipment reliability, cost and qualification remain key challenges. The $1.4 billion revenue funnel is potential full-production-year value of engaged opportunities, active designs and design wins—not contracted revenue or backlog. The November 2022 strategic-account MOU was non-binding.
- Technology and markets: Enovix reported demonstrating over 1,000 Wh/l energy density on an adjusted cell-phone-size basis for its EX1.5 development node. It cited a $23 billion 2026 addressable market estimate for targeted portable electronics. EV commercialization remains longer-term and is expected to depend on development and partnerships.
- Liquidity and capital needs: Management’s 12-month cash sufficiency estimate depends on spending, development timing and capital efficiency. Fab build-out and production scaling require substantial investment; future capital may be dilutive or unavailable on acceptable terms.
- Risks and unusual items: The company faces unproven high-volume manufacturing, supplier and raw-material risks, customer qualification and concentration risks, product reliability and battery safety risks, competition, and potential cost overruns. A $4.9 million impairment was recorded for automation work discontinued in Q4. A securities class action filed in January 2023 alleges misstatements concerning manufacturing scale-up; a separate wage-and-hour class action was in mediation, with an accrued liability recorded but not quantified in the supplied text.
- Management and controls: CEO Harrold Rust retired in January 2023; Raj Talluri became CEO. The CTO retired and the Chief Commercial Officer resigned after year-end. Management and the auditor concluded that internal control over financial reporting was effective as of January 1, 2023; the auditor issued unqualified opinions on the financial statements and internal controls.
Important facts for investors to verify
- Whether Fab-1 yield, throughput, uptime and unit economics improve enough to support commercial-scale production and customer qualification.
- Whether the planned Agility Line and Fab-2 facility meet their stated timing, and whether Fab-2 is secured and funded.
- How much of the revenue funnel converts into binding purchase orders, repeat product sales and recognized product revenue; the funnel itself is not contracted revenue.
- Whether available cash remains sufficient as operating losses and capital spending continue, and whether additional financing or dilution becomes necessary.
- Developments in the securities and wage-and-hour litigation, product safety and reliability testing, and customer or supplier concentration.